Lyell ImmunopharmaLYEL
13F holders, Q4 2025 (December 31)1holders −1
0new positions
0sold out
$30.78avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Lyell Immunopharma Inc. (LYEL) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 0 sold out. The largest holder was Decheng Capital LLC ($21.3M).
- Company
- Lyell Immunopharma Inc.
- CUSIP
- 55083R104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 96,584 shares bought, net +96,584 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Decheng Capital LLC | 2.87% | Add +16.2% | 692,050 | $21.3M |
"% of holder's portfolio" is LYEL's weight in each manager's 13F, not the share of Lyell Immunopharma Inc. the manager owns.